Drug Profile
Recombinant factor VIII-Fc fusion protein - Kaifeng Pharmaceutical
Alternative Names: Factor-VIII - Kaifeng Pharmaceutical; FRSW 107Latest Information Update: 26 Nov 2023
Price :
$50
*
At a glance
- Originator Kaifeng Pharmaceutical
- Developer Jiangsu Gensciences; Kaifeng Pharmaceutical
- Class Antihaemorrhagics; Blood coagulation factors; Coagulants; Recombinant fusion proteins
- Mechanism of Action Factor VIII replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Haemophilia A
Most Recent Events
- 18 Nov 2023 Jiangsu Gensciences plans a phase III trial in Haemophilia A (In infants, In children, Treatment-experienced) in China (Parenteral, Injection) in November 2023 (NCT06136507)
- 10 Dec 2022 Jiangsu Gensciences plans to submit a Biologic License Application (BLA) to The National Medical Products Administration (NMPA) for Haemophilia A (Treatment, Prevention, In adolescents, In adults) in China
- 10 Dec 2022 Adverse events, efficacy and pharmacokinetics data from a phase III trial in Haemophilia A presented at the 64th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2022)